Hvivo expects Continued Growth with Record Year in 2023

Clinical trials play a vital role in the discovery, testing, and eventual marketing of new drugs. Over a million individuals participated in clinical trials during 2022/23, involving more than 6,000 studies. Understanding eligibility criteria for clinical

In WVC Washington’s discussion with Dr Catchpole, they gain further insight into human challenge trials and how hVIVO is aiding the community in vaccine development. hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a

Background A SARS-CoV-2 controlled human infection model (CHIM) has been successfully established inseronegative individuals using a dose of 1×101 50% tissue culture infectious dose (TCID50) pre-alpha SARS-CoV-2 virus. Given the increasing prevalence of seropositivity to SARS-CoV-2,

Clinical trials play an important role in helping to ensure new drugs can be discovered, tested for safety and efficacy, and ultimately make their way onto the market. Over a million people took part in clinical trials during

The European Mediscience Awards is now in its 22nd year, having been held every year since inception in 2002*. The event is the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe.

hLAB is a highly specialised virology and immunology laboratory offering a suite of services to support pre-clinical and clinical respiratory drug and vaccine discovery and development. Their work includes assay development, transfer and optimization across immunology, molecular

Hvivo, a pharmaceutical services company formerly known as Open Orphan, said it remained on track to hit its future growth targets after another record year in 2023. The company is set to begin paying annual dividends,

Healthcare company hVIVO, formerly Open Orphan, has reported higher revenues and earnings for 2023 and said it had a robust orderbook for this year. The company – which tests infectious and respiratory disease products using human

hVIVO plc, a specialist in testing infectious and respiratory disease products using human challenge clinical trials, has reported a 16% increase in revenue for 2023 to £56m. The company, listed on AIM in London and Euronext

Pharmaceutical services firm Hvivo, formerly Open Orphan, reported a 44pc rise in earnings in 2023 in a “record year across all financial and operational metrics.” Earnings before interest, taxes, depreciation and amortisation (Ebitda) increased to £13m

Introduction A biotech company developing a treatment for cancer and immune disorders planned to conduct their Phase 1b clinical trial in the United States (US). They approached Venn Life Sciences seeking a partner to provide comprehensive

Andrew will be discussing new advances in respiratory virus challenge models improving their value for vaccine efficacy testing and host response disease monitoring. The World Vaccine Congress is an award-winning series of conferences and exhibitions that

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

Clinical trials are essential processes in the field of medicine, helping to determine the safety and effectiveness of new treatments, drugs, or medical procedures. These trials involve volunteers who agree to participate in the study under carefully controlled

Despite scientific progress made in the last decades, nearly 1 billion of individuals are affected by tropical diseases yearly, according to the World Health Organization. The development of new vaccines for tropical diseases remains difficult and

Canary Wharf is set to receive a multi-million-pound cash injection to build more homes in the capital’s banking district. As part of the Spring Budget, Chancellor Jeremy Hunt announced he would pour over £242m into developing homes in